These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33305109)

  • 1. A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).
    Itano Y; Kato S; Tsuboi M; Kasuga H; Tsuruta Y; Sato F; Hishida M; Ishimoto T; Kosugi T; Ando M; Kuwatsuka Y; Maruyama S
    Kidney Int Rep; 2020 Dec; 5(12):2168-2177. PubMed ID: 33305109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
    Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis.
    Hashimoto Y; Kato S; Kuro-O M; Miura Y; Itano Y; Ando M; Kuwatsuka Y; Maruyama S
    Nephrology (Carlton); 2022 Sep; 27(9):763-770. PubMed ID: 35749253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
    Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
    Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
    Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
    Khan BA; Qu X; Hua Y; Javaid MM
    Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients.
    Xipell M; Montagud-Marrahi E; Rubio MV; Ojeda R; Arias-Guillén M; Fontseré N; Rodas L; Vera M; Broseta JJ; Torregrosa V; Filella X; Maduell F
    Blood Purif; 2019; 48(2):106-114. PubMed ID: 30699421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
    Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
    Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.
    Wolf M; Block GA; Chertow GM; Cooper K; Fouqueray B; Moe SM; Sun Y; Tomlin H; Vervloet M; Oberbauer R
    Clin Kidney J; 2020 Feb; 13(1):75-84. PubMed ID: 32082556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
    Dudar I; Shifris I; Dudar S; Kulish V
    Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Cunningham J; Block GA; Chertow GM; Cooper K; Evenepoel P; Iles J; Sun Y; Ureña-Torres P; Bushinsky DA
    Kidney Int Rep; 2019 Jul; 4(7):987-994. PubMed ID: 31317120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life".
    Russo D; Tripepi R; Malberti F; Di Iorio B; Scognamiglio B; Di Lullo L; Paduano IG; Tripepi GL; Panuccio VA
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
    Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.
    Eidman KE; Wetmore JB
    Int J Nephrol Renovasc Dis; 2018; 11():69-80. PubMed ID: 29440923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study.
    Mima A; Tansho K; Nagahara D; Watase K
    J Int Med Res; 2018 Nov; 46(11):4578-4585. PubMed ID: 30027791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.